Home Overview Press Room Blog Publications For Students about us
Search

About Civil Society & Human Biotechnology


"Civil society" refers to institutional political actors outside of government and private enterprise, typically nonprofit advocacy organizations and foundations. The term "non-governmental organization," or NGO, is closely related.

Civil society organizations have come to play an important role in ensuring the accountability of governments, countering the power of corporations, and contributing to democratic governance.

For most of today’s important issues – war and peace, economic growth and equity, ecological sustainability, race and gender equality, and many others – there are dense networks of civil society institutions. For the issues surrounding human biotechnologies, a civil society infrastructure is just beginning to emerge. 



FBI’s New DNA Process Produces More Matches in Suspect Databaseby Devlin BarrettWall Street JournalAugust 25th, 2016In May, the Bureau reduced the number of genetic locations required for a potential match (from 10-13 to 8-9 loci), resulting in thousands of new "hits."
New Surrogacy Bill Bars Married Couples with Kids, NRIs, Gays, Live-ins, Foreignersby Express News ServiceThe Indian ExpressAugust 25th, 2016The Union Cabinet proposes draft bill to only include "altruistic surrogacy" for childless couples who have been married for at least five years.
Kuwait’s new DNA collection law is scarier than we ever imaginedby Daniel RiveroFusionAugust 24th, 2016National security policies require residents, citizens, and visitors to submit DNA samples, shaping new definitions of the country's citizenship.
Accessible Synthetic Biology Raises New Concerns for DIY Biological Warfareby Joseph NeighborVICE MotherboardAugust 23rd, 2016The monopoly on biology once held by governments and universities has been broken, posing significant challenges for the international community.
Public policy must address technology’s impact[citing CGS' Marcy Darnovsky]by John M. HeinThe Sacramento BeeAugust 13th, 2016“We need to develop habits of mind, or habits of social interaction, that will allow for some very robust public participation on the use of these powerful technologies,” says Marcy Darnovsky.
Finding Good Pain Treatment Is Hard. If You’re Not White, It’s Even Harder.by Abby GoodnoughThe New York TimesAugust 9th, 2016Researchers have found evidence of racial bias and stereotyping in recognizing and treating pain among people of color, particularly black patients.
The surprisingly small benefit of some very (expensive) Big Ideasby Joe GibesBioethics @ TIUAugust 5th, 2016A new article in JAMA looks at the unfulfilled hype that has become entrenched the fields of stem cells, genetics, and electronic health records.
The $100,000-Per-Year Pill: How US Health Agencies Choose Pharma Over Patientsby Fran QuigleyTruthoutAugust 5th, 2016Big Pharma wasn't always the beneficiary of US government-funded medicine breakthroughs - until the 1980s and the Bayh-Dole Act.
In crisis-hit Venezuela young women seek sterilisationby Alexandra UlmerReutersAugust 3rd, 2016Food shortages, inflation, crumbling medical sector, and anti-abortion climate have caused a growing number of women to reluctantly opt for tubal ligations.
We’re on the cusp of a gene editing revolution, are we ready?by EditorialNew ScientistJuly 27th, 2016Fast-moving genetic technologies may be on the road to outpacing public acceptance and debate.
Displaying 1-10 of 620  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760